Resource Logo
PR Newswire

Human Genome Sciences Provides Update of Company Progress - Clinical Studies of a Human Monoclonal Antibody to TRAIL Receptor-1


- Preliminary Clinical Data for Albutropin(TM) And Albuferon(TM)-alpha Phase 1 presented - Funding Assured, with $1.6 Billion in Cash and Equivalents -

ROCKVILLE, Md., April 30 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today told approximately 200 financial analysts in New York that the company expects to file four Investigational New Drug (IND) applications in 2002, seeking clearance from the U.S. Food and Drug Administration (FDA) to begin clinical trials of its new drugs. In a press release issued earlier today, Human Genome Sciences announced that it has received FDA clearance to begin clinical development of a novel anticancer drug, a human monoclonal antibody to TRAIL Receptor-1 (TRAIL-R1 mAb).(1) (A webcast of today's Human Genome Sciences Annual Analyst and Investor Meeting may be accessed at .)

William A. Haseltine, Ph.D., Chairman and Chief Executive Officer, said, "TRAIL-R1 mAb is an exciting new drug with a novel mechanism of action. It may eventually offer a promising therapeutic option for the treatment of certain solid tumors and cancers of hematopoietic origin. It is one of two IND applications we have filed so far in 2002. The other IND application, which is currently pending review at FDA, is for another novel anticancer compound, LymphoRad(TM)(131). We are seeking clearance to investigate LymphoRad(131) for use in treating multiple myeloma and other B-cell tumors.(2) We hope to file two additional IND applications this year for new Human Genome Sciences drugs."

During the meeting, Human Genome Sciences executives highlighted the following key points:

* Human Genome Sciences has a rich product pipeline of clinical and advanced preclinical compounds, including seven drugs in clinical trials -- (1) TRAIL-R1 mAb for the treatment of solid tumors and cancers of hematopoietic origin; (2) LymphoStat-B(TM) for the treatment of lupus and rheumatoid arthritis; (3) BLyS(TM) (B-lymphocyte stimulator) for common variable immune disorder (CVID) and immunoglobulin-A deficiency; (4) Repifermin for venous ulcers and cancer therapy-induced mucositis; (5) Albuferon(TM) for the treatment of hepatitis C and chronic myelogenous leukemia; (6) Albutropin(TM) for the treatment of growth hormone deficiency; and (7) Albuleukin(TM) for the treatment of solid tumors.

* Encouraging preliminary interim clinical data were presented from ongoing Phase 1 clinical studies of Albutropin (albumin-human growth hormone) and Albuferon-alpha (albumin-interferon alpha-2b).

* Human Genome Sciences' pipeline includes seven drugs in clinical development, one drug that is currently pending FDA clearance to begin clinical trials, and many drugs in preclinical development. Each of these drugs is intended for use in meeting significant unmet medical needs.

* Human Genome Sciences' current pipeline is comprised of roughly two thirds novel human protein drugs and antibody drugs arising from genomics-based research, and one third new improved long-acting versions of existing protein drugs.

* The success of Human Genome Sciences' drug discovery efforts rests firmly on the company's expertise in genomics, the systematic collection and understanding of human genes and their functions, as well as its exclusive focus on developing human protein and antibody drugs.

* Human Genome Sciences now has more than 1,000 highly skilled employees, with a concentration on protein and antibody drug development and manufacturing.

* Human Genome Sciences has protein and antibody manufacturing capabilities in bacteria, yeast and mammalian cells, and is constructing a commercial-scale protein and antibody drug manufacturing facility that will enable the company to produce several different protein and antibody drugs simultaneously.

* With $1.6 billion in cash and equivalents, Human Genome Sciences has the financial strength necessary to advance that objective.

Albutropin and Albuferon-alpha Clinical Trials - Preliminary Results Preliminary interim results of the open-label Phase 1 dose-escalating safety trials of Albutropin and Albuferon-alpha were discussed. As expected, both Albutropin and Albuferon-Alpha demonstrated substantially longer half- life in serum than did the parental compounds.

Surrogate marker data were also presented for both drugs. The significance of the surrogate marker data must be tempered by the very preliminary and interim nature of the results. These results were obtained at intermediate dose levels in the dose-escalation safety trials. Nonetheless, the results were encouraging.

The level of insulin-like growth factor-1 (IGF-1) in serum is a robust surrogate marker for the biological activity of human growth hormone. Higher single doses of Albutropin were found to be capable of inducing prolonged elevations in the level of IGF-1 in some patients. Phase 1 studies of Albutropin continue. Dose-escalation studies are in progress using single doses. Repeat dosing is now planned since biological responses are being observed.

Phase 1 studies of Albuferon-alpha are in progress with patients who have failed interferon treatment for Hepatitis-C (HCV) and continue to test positive for active serum hepatitis-C virus. Levels of the enzyme, 2', 5'- oligoadenylate synthetase (OAS), provide a surrogate marker for interferon- alpha activity. A single dose of Albuferon-alpha has been demonstrated to be capable of inducing elevated OAS levels for up to 28 days. More remarkably, the HCV viral load was reduced by half a log in some patients treated with a single dose. Along with continued escalation of single-dose exposure, repeat dosing has been initiated to further assess safety and the durability of biological activity. Once again, it is important to stress the relatively small number of patients studied and the preliminary nature of the data.

Craig A. Rosen, Ph.D., Executive Vice President, Research and Development, and David C. Stump, M.D., Senior Vice President, Drug Development, reported on the progress of a number of Human Genome Sciences' drugs in clinical and preclinical development.

Dr. Rosen said, "We have an exceptionally rich product pipeline of clinical and advanced preclinical compounds. Seven of our drug candidates are now in clinical development. These include two therapeutic proteins, two human monoclonal antibodies, and three improved long-acting versions of existing therapeutic proteins. We expect soon to receive FDA clearance to begin human clinical study of a radiolabeled protein. I am not aware of another biotechnology company with the depth and breadth of quality new drug candidates that we have developed at Human Genome Sciences."


The Human Genome Sciences oncology franchise now includes nine compounds -- six anti-tumor drugs and three cancer supportive care drugs.


LymphoRad(131) is a radiolabeled form of B-Lymphocyte Stimulator (BLyS), a naturally occurring human protein discovered by Human Genome Sciences. Preclinical studies show that LymphoRad(131) binds to receptors that are found exclusively on B cells and B-cell tumors. Such tumors are sensitive to killing by the attached radioisotope. LymphoRad(131) is currently awaiting FDA clearance to begin human clinical development.

Dr. Stump said, "The recent clinical success of radiolabeled human antibodies for B-cell tumors validates the concept of LymphoRad as an antitumor drug. Initially, we plan to test LymphoRad(131) in patients suffering from multiple myeloma. Multiple myeloma tumors display receptors for LymphoRad but generally lack the CD-20 receptor, suggesting that LymphoRad(131) may provide a novel treatment option for people with such disease. LymphoRad(131) has the potential to treat a broad range of other B- cell tumors as well, including large B-cell lymphomas, follicular B-cell lymphomas, chromic lymphocytic leukemia, and Burkitt's lymphoma. The need for new treatments for B-cell cancers is great. I look forward to the prospect of initiating clinical study of LymphoRad(131) in the second half of 2002."

TRAIL-R1 and TRAIL-R2 Receptor Antibodies

The TRAIL-R1 and TRAIL-R2 "death receptors" are found on the surface of many solid tumors. Human Genome Sciences announced today that it has received FDA permission to begin clinical study of TRAIL-R1 mAb, a human monoclonal antibody to TRAIL Receptor-1.(1) Both antibodies trigger the death of receptor-bearing tumors. These antibodies may have an advantage over the natural TRAIL ligand, as they do not recognize so-called "decoy receptors" that are often displayed on the surface of tumors in addition to the active receptor.

Dr. Rosen said, "The emergence of death receptors as targets for anticancer research has generated considerable excitement in the oncology community. TRAIL-R1 mAb is an agonistic antibody that stimulates activity. To my knowledge, TRAIL-R1 mAb is the first human agonistic antibody to enter clinical trials."

Dr. Stump said, "We believe that TRAIL-R1 mAb has significant potential for use in treating a broad range of cancers and look forward to investigating its use in clinical trials. Preclinical studies suggest that TRAIL-R1 mAb may have therapeutic benefit in the treatment of human malignancies either as a single agent or in combination with chemotherapy. Following completion of the initial Phase 1 study to evaluate the drug's safety and pharmacology, we hope to explore the use of TRAIL-R1 mAb in treating a number of tumor types."

TRAIL-R2 mAb, a human monoclonal antibody that recognizes TRAIL Receptor- 2, is in preclinical development.

Albuleukin and Albuferon-alpha

Albuleukin(TM) and Albuferon(TM)-alpha are new long-acting versions of the existing protein drugs interleukin-2 and interferon-alpha. Both drugs are active antitumor drugs. These new compounds were constructed by Human Genome Sciences scientists by fusing the gene for the existing drug to human albumin.

The resulting fusion protein retains the activity of the parent compound, but may have several advantages. Both Albuleukin and Albuferon-alpha have an extended half-life in serum and may display reduced toxic effects as compared to the original drugs. Both compounds have been approved for clinical trials for the treatment of cancers.(3),(4) Enrollment for studies should proceed throughout 2002. Albuferon-alpha is also the subject of an ongoing Phase 1 study for use in treating hepatitis-C (see below under AUTOIMMUNITY AND IMMUNOLOGY).

VEGF-2 Monoclonal Antibody

Vascular Endothelial Growth Factor-2 (VEGF-2) is a human protein discovered by Human Genome Sciences that stimulates formation of both blood and lymph vessels. Studies in the scientific literature implicate VEGF-2 as important for the metastatic spread of breast and melanoma tumors to lymph nodes. The company has developed a human monoclonal antibody that neutralizes the activity of VEGF-2 and is an active antitumor agent in preclinical studies. Additional laboratory studies in progress are designed to test the suitability of VEGF-2 monoclonal antibody as a clinical candidate.


Three of the nine cancer drugs in Human Genome Sciences' cancer pipeline have a primary indication for supportive care of patients undergoing chemotherapy. These include Albupoietin, Albugranin and Repifermin.

Albupoietin and Albugranin

Albupoietin(TM) and Albugranin(TM) are new long-acting versions of erythropoietin and granulocyte colony stimulating factor (G-CSF) respectively. Both Albupoietin and Albugranin may help patients recover from damage to their blood-forming tissues. Albupoietin should act to restore red cell levels to combat anemia, whereas Albugranin should stimulate the replacement of missing neutrophils to help prevent infections. Preclinical studies show that Albupoietin compares favorably both in terms of activity and half-life with both erythropoietin and the new modified version of erythropoietin called Aranesp(TM). The preclinical profile of Albugranin also indicates that it is comparable to Neulasta(TM) and has a longer half-life than G-CSF, while retaining activity.(5) This combination of activity and half-life is such that administration of one dose of the drug per round of chemotherapy may be feasible. Human Genome Sciences recently announced plans to accelerate development of Albugranin, and reported today on advanced preclinical studies of Albupoietin.


Repifermin is a human protein we discovered that promotes the healing of wounds to the mucosal tissue. The primary indication for this drug is the repair of wounds to the skin (see TISSUE REPAIR below). Human Genome Sciences' initial clinical studies of Repifermin showed repifermin to be both well tolerated and active in helping to heal wounds.(6) Repifermin may also be used to protect cancer patients from damage to the mucosal tissue arising from chemotherapy and radiation treatments.(7)

The company's initial Phase 2 study of Repifermin for protection of oral mucositis showed the drug to be well tolerated. However, at the doses tested, no activity was demonstrated in this trial, in which the drug was administered after chemotherapy. Preclinical experiments now suggest that Repifermin may be more active when given prior to mucosal injury. We are conducting a second trial of Repifermin for the prevention of oral mucositis in which the drug is administered both before and after chemotherapy.(8)


Many chronic diseases result from mis-regulation of the immune system, including autoimmune diseases as well as immunodeficiencies. Additionally, the immune system may be mobilized to fight chronic infections. Human Genome Sciences is developing four drugs in this therapeutic area.


LymphoStat-B(TM) is the human monoclonal antibody that inactivates B- Lymphocyte Stimulator (BLyS), a protein discovered by Human Genome Sciences that stimulates the production of antibodies. The company's scientists, along with others, have reported in the scientific literature that some patients with systemic lupus erythematosus and severe arthritis have elevated levels of BLyS in their circulation. Excessive amounts of the protein induce lupus in laboratory studies. Overproduction of autoimmune-inducing antibodies may be counteracted by reducing BLyS levels with LymphoStat-B. Human Genome Sciences has initiated a Phase 1 clinical trial of LymphoStat-B in systemic lupus erythematosus and will be enrolling patients into the study throughout the year.(9)

Dr. Stump said, "LymphoStat-B has generated considerable enthusiasm in the lupus clinical community. Enrollment in our initial Phase 1 study is going very well. This drug has the potential to treat a family of serious autoimmune diseases. If the initial Phase 1 trials are successful, we hope to be able to add new indications for additional trials for patients with rheumatoid arthritis and other autoimmune diseases."

B-Lymphocyte Stimulator (BLyS)

B-Lymphocyte Stimulator is a human protein discovered by Human Genome Sciences that stimulates the production of increased levels of antibodies. The drug acts to increase the number and activity of antibody-producing plasma cells. We currently are conducting Phase 1 clinical studies of BLyS(TM) in patients with antibody deficiency diseases, including common variable immunodeficiency disease (CVID)(10) and deficiencies in one specific type of antibody, immunoglobulin-A.(11) We have been granted orphan drug status for treatment of CVID patients with BLyS.(12) Enrollment for these studies should proceed throughout 2002.

Albuferon-alpha and Albuferon-beta

Albuferon(TM)-alpha and Albuferon(TM)-beta are new long-acting forms of interferon-alpha and interferon-beta, respectively. The drugs were created by fusing the genes for the parent drug to that for human albumin. Preclinical studies show that both drugs are active and have longer half-lives than do the original compounds.

Human Genome Sciences has initiated human trials for Albuferon-alpha for the treatment of patients with hepatitis C.(13) Interferon-alpha alone has been shown to be an effective antiviral drug. We hope that Albuferon-alpha will be more effective and perhaps better tolerated than interferon-alpha. Albuferon-alpha is also the subject of clinical study for use in treating chronic myelogenous leukemia (see ONCOLOGY -- ANTI-TUMOR DRUGS, above).

Dr. Stump said, "The preliminary clinical data presented today seem to confirm our preclinical findings that Albuferon-alpha demonstrates substantially longer half-life in serum than does interferon-alpha. While it is important to stress the small number of patients and the preliminary nature of the data, it is well known that levels of the OAS enzyme constitute an important surrogate marker for interferon-alpha activity. To see indications that a single dose of Albuferon-alpha may be capable of inducing elevated OAS levels for up to 28 days is encouraging. To also see patients respond who were previously shown to be resistant to interferon-alpha is even more encouraging."

Interferon-beta has been demonstrated to be an effective treatment for patients with multiple sclerosis. However, the dosing regimen as well as the side effects of interferon-beta are less than optimal. Albuferon-beta may address patient needs in both areas. The long-acting properties of Albuferon- beta compared with the parent compound may allow less frequent dosing, while the dose schedule and sustained activity of Albuferon-beta may also reduce side effects. Human Genome Sciences is currently conducting additional preclinical tests designed to support an IND application for Albuferon-beta.


Diabetes, obesity and other metabolic disorders pose serious and growing threats to health. Human Genome Sciences recently initiated systematic efforts to discover new human proteins and antibodies that could be used to treat these diseases. The company now has five new drug candidates in this therapeutic area.

GMAD-1 and GMAD-2

GMAD-1 is a novel human protein that emerged from Human Genome Sciences' screening programs designed to find new proteins and antibodies to treat diabetes and obesity. It affects multiple metabolic pathways involved in diabetes and obesity. GMAD-2 is a monoclonal antibody active in the same pathway as GMAD-1. Human Genome Sciences continues to explore the fundamental biology of GMAD-1 and GMAD-2 and to conduct additional preclinical experiments designed to enable the company to translate this exciting discovery into new compounds that may be used to treat both diabetes and obesity.


There is a recognized need to establish and maintain a low basal level of insulin activity in patients with Type 1 and Type 2 diabetes. Albulin is a novel long-acting form of insulin. The drug was created by fusing the gene for human insulin to that for human albumin. In preclinical studies, Albulin is active in reducing blood glucose levels for a prolonged period. Additional preclinical studies are in progress to support an IND application for this drug candidate for the treatment of Type 1 and Type 2 diabetes. Preclinical studies suggest that Albulin may perform better than Glargine(TM), the current best candidate for a slow-acting drug.


Albugon is a long-acting form of a human peptide that has been demonstrated to lower blood glucose levels in patient and animal studies. Albugon was created by fusing a gene developed to produce an active form of the peptide to the gene for human albumin. Preclinical studies are in progress to support an IND application. These studies demonstrate that Human Genome Sciences' albumin fusion technology can be used to create long-acting peptide drugs.


Albutropin is a long-acting form of human growth hormone. The drug was created by fusion of the gene for human growth hormone to that for human albumin. Albutropin has a longer half-life in serum than does growth hormone itself. Preclinical studies demonstrate that Albutropin stimulates increased serum levels of insulin-like growth factor (IGF-1), a natural messenger for the metabolic effects of growth hormone.

The primary indication of Albutropin is metabolic, for the treatment of growth hormone deficiency. A Phase 1 clinical trial is underway in growth hormone-deficient adults.(14) Preliminary data from this trial was presented at today's meeting. Human Genome Sciences also intends to evaluate Albutropin for the treatment of growth hormone-deficient children as soon as its safety has been demonstrated in adults.

Dr. Stump said, "Levels of insulin-like growth factor-1 (IGF-1) are known to be a robust surrogate marker for the biological activity of human growth hormone. Preliminary data from a small number of patients in the current Phase 1 study indicate that higher single doses of Albutropin can produce prolonged elevations in the level of IGF-1. These results were obtained at intermediate dose levels in the dose-escalation process and are clearly supportive of our objectives for Albutropin, although it is important to maintain the perspective that these data are preliminary and interim, and that we must await the final study results before coming to firm conclusions."


Human Genome Sciences is developing two drugs in the area of tissue repair, one to repair wounds to the skin and gastrointestinal tract, and a second to treat injuries to the lung. The company believes that many more naturally occurring human proteins will eventually be discovered that may be used to repair a wide variety of tissue injuries.


Repifermin is a human protein discovered by Human Genome Sciences that stimulates the repair of injured skin and mucosal tissues (also see ONCOLOGY -- CANCER SUPPORTIVE CARE, above). Human Genome Sciences is conducting clinical trials of Repifermin in patients with chronic skin ulcers. Preliminary trials demonstrated that Repifermin is active and well tolerated for the formation of new skin in patients with venous ulcers, when compared to a placebo control group. A large Phase 2B clinical trial of Repifermin for the treatment of venous ulcers is underway, which is designed to demonstrate its ability to completely heal these wounds.


LF-B25 is a human protein Human Genome Sciences discovered that is active in stimulating the growth of at least two important cell types in the lung. LF-B25 stimulates the growth of type 2 alveolar cells, leading to the possibility that it may be used to treat patients with both chronic and acute lung injury. The drug candidate also stimulates the growth of bronchial endothelial cells and may therefore be used for the treatment of patients with emphysema. Human Genome Sciences is currently exploring the range of applications for this exciting new drug candidate and is working to develop convenient and effective formulations for deep lung delivery.


Osteoporosis is a serious and growing medical problem in the aging population. Human Genome Sciences has discovered two human proteins that may be useful for the treatment of this disease. The company also has designed two long-acting forms of proteins known to affect bone metabolism.


The drug candidate Albutegrin, is a long-acting form of a human protein that Human Genome Sciences discovered. The parent protein inhibits formation of osteoclasts, cells that destroy bone. Studies suggest that the protein plays an active role in inhibiting bone loss. Albutegrin was created by fusion of the gene that encodes the osteoclast inhibitory protein to that for human albumin. Human Genome Sciences judged it preferable to begin studies of Albutegrin with a long-acting, rather than a short-acting, form of the protein. Preclinical studies in progress are designed to support the feasibility of developing this clinical candidate.


Osteostat is a second human protein discovered by Human Genome Sciences that inhibits formation of osteoclasts and acts by a novel mechanism distinct from that of Albutegrin. Preclinical experiments show that Osteostat plays an important role in bone metabolism. The company is currently conducting additional preclinical experiments to evaluate how this new protein might be used to treat and prevent osteoporosis.

Albutonin and Albuthyrin

Albutonin and Albuthyrin are novel long-acting forms of the human peptides calcitonin and parathyroid hormone, both of which stimulate bone formation. These drugs were created by fusing a gene designed to produce the protein to the gene for human albumin. The resultant proteins possess the activity of the proteins themselves, yet have a longer serum half-life. Human Genome Sciences is conducting additional preclinical studies with both drug candidates to support separate IND applications.


HIV/AIDS is a serious threat to health worldwide. The number of infected patients is rising rapidly; and strains of HIV resistant to many drugs account for up to half the infections in developed countries. New antiviral drugs to treat the disease and drugs to support AIDS patients are urgently needed.

CCR5 mAb

CCR5 is a human chemokine receptor that is required for HIV infection. Human Genome Sciences was the first to discover this receptor and recognize its natural function. Drugs that block binding of HIV to CCR5 block infection and therefore may be useful for treatment of the disease. Human Genome Sciences has developed a human monoclonal antibody to CCR5 that inhibits HIV infection. The company is conducting preclinical studies designed to support an IND application for this candidate. The development of anti-CCR5 drugs is a competitive area associated with complex patent applications. Human Genome Sciences has been issued a patent that describes the CCR5 gene and some of its uses.


HGS-HIV/AIDS 27 (HGS-H/A 27) is a long-acting version of a human protein discovered by Human Genome Sciences that inhibits HIV replication. The natural form of the protein has a potent inhibitory effect on virus replication in cell culture. The company created HGS-H/A 27 by fusion of the gene that encodes the HIV inhibitory protein to that for human albumin. Human Genome Sciences believes that a long-acting form of the protein may have improved antiviral properties compared to the parent compound, and is currently conducting preclinical experiments with this drug.


Human Growth Hormone (hGh) is approved for the treatment of AIDS wasting syndrome. A long-acting form of hGh should be attractive for this use as well.

For additional information on Human Genome Sciences, please visit our web site at . Health professionals interested in clinical studies involving HGSI products are encouraged to inquire via the Contact Us section of the Human Genome Sciences web site, , or by calling us at 301-610-5790, extension 3550.

Human Genome Sciences is a company with the mission to treat and cure disease by bringing new gene-based drugs to patients.

HGS, Human Genome Sciences, Albuferon, Albugranin, Albuleukin, Albupoietin, Albutropin, BLyS, LymphoRad and LymphoStat-B are trademarks of Human Genome Sciences, Inc. All other trademarks and tradenames are the property of their respective owners.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the company's unproven business model, dependence on new technologies, uncertainty and timing of clinical trials, ability to develop and commercialize products, dependence on collaborators for services and revenue, substantial indebtedness, intense competition, uncertainty of patent and intellectual property protection, dependence on key management, uncertainty of regulation of products, dependence on key suppliers, the impact of future alliances or transactions and other risks that may be described in the company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. Human Genome Sciences undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.


1. April 30, 2002: Human Genome Sciences Initiates Trial of Novel Anticancer Drug

2. January 23, 2002: Human Genome Sciences Files Investigational New Drug Application For Lymphorad131

3. January 7, 2002: Human Genome Sciences Initiates Trial of Albuleukin(TM), a Recombinant Human Protein for Treating Solid Tumor Cancers.

4. See Albuferon-alfa product backgrounder at .

5. April 15, 2002: Human Genome Sciences Announces Development Plans for Drugs to Treat Chemotherapy-Induced Neutropenia

6. February 10, 1999: Human Genome Sciences Initiates Phase 2 Human Clinical Trials of KGF-2, a New Wound-Healing Drug

7. January 19, 2000: Human Genome Sciences Announces Phase 2 Human Clinical Trials of Repifermin for Cancer Treatment Related Mucositis

8. December 7, 2001: Results of Two Phase 2a Clinical Trials Show Excellent Safety Profile for Repifermin

9. November 1, 2002: Human Genome Sciences Initiates Trial of a New Drug for Systemic Lupus Erythematosus and Other Autoimmune Diseases

10. June 23, 2000: Human Genome Sciences to Initiate Human Clinical Trials Of BLyS

11. September 19, 2001: Human Genome Sciences Announces Trial for Treatment of Immunoglobulin-A Deficiency

12. February 27, 2001: Human Genome Sciences Receives Orphan Drug Designation for BLyS, Therapeutic Protein for Treatment of Common Variable Immunodeficiency

13. March 23, 2001: Human Genome Sciences Begins Phase 1 Clinical Trial of Albuferon in Hepatitis C Patients

14. June 5, 2001: Human Genome Sciences' Albutropin(TM) IND Cleared By FDA


Copyright © 2002 -PR Newswire, Publisher. All rights reserved to PR Newswire.. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PR Newswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019.

Information in this article was accurate in April 30, 2002. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.